A new item has been added to the shopping cart

×
×

Tell to a friend

Your Name:
E-mail of your friend:
Message:
Captcha CAPTCHA code
Enter the text in the image above

×

Already a subscriber? Log in now for online Access.

×

Artículo Tomo 71, Número. 8, Octubre 2018

Archivos Españoles de Urología

Aggressive variants of castration resistant prostate cancer (crpc): neuroendocrine prostate cancer.

Authors: Fernando Vįzquez-Alonso, Ignacio Puche-Sanz y José Manuel Cózar-Olmo.

Arch. Esp. Urol. 2018; 71 (8): 735-743

Vol. 71, Number. 8, October 2018

OBJECTIVES: There is no broad consensus about what diagnostic tests use for CRPC follow up as well as their frequency. Our objective is to review and analyze the most important CRPC follow up patterns described in the literature to date.

METHODS: We performed a critical analysis of the recommendations for follow up most universally employed (PCWG3, RADAR, St Gallen consensus, NCCN guidelines, EAU guidelines)

RESULTS: CT scan and bone scan are the routine recommended diagnostic tests, in front of other techniques such as PET/CT or MRI, that may improve the diagnostic efficacy but they have the problem of availability and lack of internal validity for follow up.

CONCLUSIONS: Follow up is different for non metastatic and metastatic CRPC. For nm CRPC, it is recommended to perform monitoring that includes PSA and imaging tests, without consensus about periodicity. For mCRPC, it is recommendable to do follow up with periodic PSA and imaging tests, since it is possible to have radiological progression without PSA progression.

ONLY IN SPANISH


Only subscribers


Copyright © 2015 | Valid support N°12/08-W-CM | ISSN-ONLINE: 1576-8260 |